Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype

Liver International

Volumn 34, Issue 7, 2014, Pages 1084-1093

  Farrell, Geoffrey C ^a   Mridha, Auvro R ^a   Yeh, Matthew M ^b   Arsov, Todor ^a   Van Rooyen, Derrick M ^a   Brooling, John ^a   Nguyen, Tori ^a   Heydet, Deborah ^a   Delghingaro Augusto, Viviane ^a   Nolan, Christopher J ^a   Shackel, Nicholas A ^c   Mclennan, Susan V ^d   Teoh, Narci C ^a   Larter, Claire Z ^a  

^a CANBERRA HOSPITAL   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTENARY INSTITUTE   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cytokines; Fibrosis; Growth factors; Non alcoholic steatohepatitis; Strain difference

Indexed keywords

ALMS1 PROTEIN, MOUSE; CYTOKINE; DNA BINDING PROTEIN; MATRIX METALLOPROTEINASE; SIGNAL PEPTIDE;

ADVERSE EFFECTS; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; LIPID DIET; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; NONOBESE DIABETIC MOUSE; PATHOLOGY; SPECIES DIFFERENCE;

ANALYSIS OF VARIANCE; ANIMALS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DNA-BINDING PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; NON-ALCOHOLIC FATTY LIVER DISEASE; SPECIES SPECIFICITY;

EID: 84904503999     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12335     Document Type: Article

References (38)

1. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-25.
2. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25: 672-90.
3. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-51.
4. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
5. Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-9.
6. Lo L, Mclennan SV, Williams PF, et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol 2011; 55: 435-44.
7. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
8. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
9. Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 1567-76.
10. Collin GB, Marshall JD, Ikeda A, et al. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom syndrome. Nat Genet 2002; 31: 74-8.
11. Marshall JD, Beck S, Maffei P, Naggert JK. Alstrom Syndrome. Eur J Hum Genet 2007; 15: 1193-202.
12. Arsov T, Silva DG, O'bryan MK, et al. Fat Aussie-A new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol Endocrinol 2006; 20: 1610-22.
13. Heydet D, Chen LX, Larter CZ, et al. A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice. Dev Neurobiol 2012; 73: 1-13.
14. Larter CZ, Yeh MM, Van Rooyen DM, et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658-68.
15. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-403.
16. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61.
17. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
18. Min D, Lyons JG, Jia J, Lo L, Mclennan SV. 2-Methoxy-2, 4-diphenyl-3(2H)-furanone-labeled gelatin zymography and reverse zymography: A rapid real-time method for quantification of matrix metalloproteinases-2 and -9 and tissue inhibitors of metalloproteinases. Electrophoresis 2006; 27: 357-64.
19. Mook OR, Van Overbeek C, Ackema EG, Van Maldegem F, Frederiks WM. In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J Histochem Cytochem 2003; 51: 821-9.
20. Biswas C, Zhang Y, Decastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-9.
21. Larter CZ, Yeh MM, Haigh WG, et al. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease. Obesity 2013; 21: 1189-99.
22. Bell-Anderson KS, Aouad L, Williams H, et al. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. Int J Obes 2011; 35: 1539-48.
23. Larter CZ, Yeh MM, Van Rooyen DM, et al. Peroxisome proliferator-activated receptor-α agonist, Wy 14, 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2012; 27: 341-50.
24. Van Rooyen DM, Gan LT, Yeh MM, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013; 59: 144-52.
25. Bhathal PS, Rose NR, Macay IR, Whittingham S. Strain differences in mice in carbon tetrachloride-induced injury. Br J Exp Pathol 1983; 64: 524.
26. Wang M-E, Chen Y-C, Chen IS, et al. Curcumin protects against thioacetamide-induced hepatic fibrosis by attenuating the inflammatory response and inducing apoptosis of damaged hepatocytes. J Nutri Biochem 2012; 23: 1352-66.
27. Van De Vijver KK, Colpaert CG, Jacobs W, et al. The host's genetic background determines the extent of angiogenesis induced by schistosome egg antigens. Acta Trop 2006; 99: 243-51.
28. Hillebrandt S, Goos C, Matern S, Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002; 123: 2041-51.
29. Lin X, Yue P, Chen Z, Schonfeld G. Hepatic triglyceride contents are genetically determined in mice: results of a strain survey. Am J Phisiol- Gastro Liv Phisiol 2005; 288: G1179-89.
30. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci 1997; 94: 10663-8.
31. Marra F, Romanelli RG, Giannini C, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999; 29: 140-8.
32. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
33. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26: 1-9.
34. Kodama T, Takehara T, Hikita H, et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 2011; 121: 3343-56.
35. Paradis V, Dargere D, Bonvoust F, et al. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002; 82: 767-74.
36. Eguchi T, Kubota S, Kawata K, et al. Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol 2008; 28: 2391-413.
37. Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-β on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47: 699-710.
38. Kistler KD, Brunt EM, Clark JM, et al. Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2011; 106: 460-8.